Faster-Acting Insulin Aspart Provides Faster Onset and Greater Early Exposure vs Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Pediatric Diabetes - United Kingdom
doi 10.1111/pedi.12506
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Fiasp: A New Faster-Acting Insulin Aspart Formulation for Diabetes

Prescriber
Pharmacology
2017English

The Association Between Anti‐insulin Aspart Antibodies and the Pharmacokinetic and Pharmacodynamic Characteristics of Fast‐acting Insulin Aspart in Children and Adolescents With Type 1 Diabetes

Pediatric Diabetes
Internal MedicinePediatricsEndocrinologyPerinatologyChild HealthMetabolismDiabetes
2020English

Comparison of a Soluble Co-Formulation of Insulin Degludec/Insulin Aspart vs Biphasic Insulin Aspart 30 in Type 2 Diabetes: A Randomised Trial

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2012English

Use of Short-Acting Insulin Aspart in Managing Older People With Diabetes

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2009English

A Survey of Physician Experience and Treatment Satisfaction Using Fast-Acting Insulin Aspart in People With Type 1 or Type 2 Diabetes

Postgraduate Medicine
Medicine
2020English

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Use of Fast‐acting Insulin Aspart in Insulin Pump Therapy in Clinical Practice

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

15 Years of Experience With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Drugs in R and D
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy